TODOS MED LTD ORD - TOMDF STOCK NEWS

Todos Medical, Ltd. (OTCQB: TOMDF) announced its joint venture 3CL Pharma received a Notice of Allowance from the USPTO for the SARS-CoV-2 3CL protease diagnostic test, TolloTest. This test aims to detect 3CL protease levels in human samples with PCR-like accuracy, essential in Long COVID analysis. TolloTest has potential commercialization avenues, including at-home and laboratory tests. The global COVID-19 diagnostics market could reach USD 50.1 billion by 2030, growing at a 7.7% CAGR. TolloTest is positioned to innovate point-of-care diagnostics, enhancing COVID-19 management.

Todos Medical, Ltd. (OTCQB: TOMDF) has entered into a distributor agreement with Nerd Hemp, Inc. to supply its proprietary Tollovid™ and CBD products through 5500 automated retail machines across the U.S. This rollout is expected to generate approximately $11.5 million in revenue for Q4 2022. The machines will be installed in high-traffic locations, enhancing accessibility to these health products. As distribution expands beyond online channels, Todos anticipates increased product exposure and consumer engagement, especially in light of growing demand for automated purchase options.

Todos Medical, Ltd. (OTCQB: TOMDF) has appointed NFL Hall of Famer Michael Irvin as the Sports Ambassador for its #TolloUp marketing campaign promoting the immune support supplement Tollovid™. Recent studies indicate that over 90% of users with acute infections or Long COVID found benefits from Tollovid. The product is Informed-Sport certified, ensuring it contains no banned substances. Todos emphasizes the importance of immune support for athletes during the competitive season and highlights Tollovid as a key solution to support healthy immune function.

On September 15, 2022, Todos Medical (OTCQB: TOMDF) announced a case study via its joint venture 3CL Pharma, showcasing the improvement of Long COVID symptoms in a patient following the supplementation of Tollovid. This 3CL protease inhibitor demonstrated potential efficacy in resolving symptoms associated with microclots. As Long COVID continues to affect millions, this finding highlights the need for effective management strategies. The company is also advancing its Tollovir therapeutic candidate, which targets coronaviruses, and has completed a Phase 2 clinical trial for severe COVID-19 cases.

Todos Medical, Ltd. (OTCQB: TOMDF) announced that its CLIA/CAP-certified laboratory, Provista Diagnostics, has initiated a validation plan for PCR-based polio testing. This includes developing low viral load diagnostic tests for early detection. The global bioinformatics market is expected to grow from $13.2 billion in 2021 to $45.6 billion by 2030. Todos emphasizes that wastewater surveillance is pivotal for controlling the spread of viral pathogens. The company also focuses on expanding diagnostic solutions for various diseases, including cancers and neurodegenerative disorders.

Todos Medical, Ltd. (OTCQB: TOMDF) is collaborating with The Alchemist's Kitchen to host an educational virtual event on September 20, 2022, focusing on Long COVID. The event features Dr. Leo Galland, who will discuss a 5-point strategy for managing Long COVID. It aims to empower both patients and healthcare providers amid rising cases. The initiative also supports the Survivor Corps, a foundation aiding Long COVID advocacy. Participants can register online.

Todos Medical, Ltd. (OTCQB: TOMDF) announced that Wellness Magazine featured its 3CL protease inhibitor supplement, Tollovid™, in an article highlighting its potential benefits for COVID-19 recovery. CEO Gerald Commissiong noted the growing recognition of Tollovid in addressing Long COVID, emphasizing its unique position as the only 3CL protease inhibitor on the market. The company plans to advance clinical trials for Tollovid and its therapeutic drug candidate, Tollovir™, funded by an upcoming crowdfunding initiative for its subsidiary, 3CL Pharma.

Todos Medical (OTCQB: TOMDF) announced plans for a crowdfunding campaign to support Emergency Use Authorization (EUA) filing for its COVID-19 therapeutic, Tollovir, targeting hospitalized patients. Additionally, the funds will aid in the clinical development of Tollovid and TolloTest for Long COVID. The company has finalized an agreement with NLC Pharma, granting joint venture 3CL Pharma ownership of relevant intellectual property, which includes patent applications for Tollovir and related products. A national marketing campaign for Tollovid sales is also in the works.

Todos Medical, Ltd. (OTCQB: TOMDF) recently held an interview at Nasdaq MarketSite where CEO Gerald Commissiong discussed the impacts of Long COVID on the economy. According to economist David Cutler, Long COVID could cost the US economy approximately $3.7 trillion, affecting 9.6 million people with severe symptoms. Todos, through its subsidiary 3CL Pharma, continues to develop treatments for Long COVID, including the 3CL protease inhibitor Tollovid™ and the upcoming Tollovir™. The company also highlights the significance of its diagnostic tool TolloTest™ in measuring viral activity related to Long COVID.